Ultragenyx Pharmaceutical (RARE) Equity Ratio (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Equity Ratio data on file, last reported at 0.18 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.18, down 265.9% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.18 (down 265.9% YoY), and the FY2025 annual result was 0.05, down 130.78% from the prior year.
• Equity Ratio slipped to 0.18 in Q1 2026 per RARE's latest filing, from 0.05 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.58 in Q1 2022 and troughed at 0.18 in Q1 2026.
• A 5-year average of 0.17 and a median of 0.16 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2026: Equity Ratio jumped 780.18% in 2024, then tumbled 265.9% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.23 in 2022, then fell by 19.02% to 0.18 in 2023, then retreated by 8.01% to 0.17 in 2024, then slumped by 130.78% to 0.05 in 2025, then sank by 248.72% to 0.18 in 2026.
• Business Quant data shows RARE's Equity Ratio at 0.18 in Q1 2026, 0.05 in Q4 2025, and 0.01 in Q3 2025.